REMCARE: reminiscence groups for people with dementia and their family caregivers – effectiveness and cost-effectiveness pragmatic multicentre randomised trial

RT Woods,1* E Bruce,2 RT Edwards,3 R Elvish,4 Z Hoare,5 B Hounsome,3 J Keady,4 ED Moniz-Cook,6 V Orgeta,7 M Orrell,7 J Rees8 and IT Russell9

1Dementia Services Development Centre Wales, Institute of Medical and Social Care Research, Bangor University, Bangor, UK
2Bradford Dementia Group, University of Bradford, Bradford, UK
3Centre for Health Economics and Medicines Evaluation, Institute of Medical and Social Care Research, Bangor University, Bangor, UK
4School of Nursing, Midwifery and Social Work, University of Manchester/Greater Manchester West Mental Health NHS Foundation Trust, Manchester, UK
5North Wales Organisation for Randomised Trials in Health (and Social Care), Institute of Medical & Social Care Research, Bangor University, Bangor, UK
6Centre for Mental Health and Aging, Humber Mental Health Teaching NHS Trust, Coltman Street Day Hospital, Kingston-upon-Hull, UK
7Department of Mental Health Sciences, University College London, London, UK
8Aneurin Bevan Health Board, Ystrad Mynach Hospital, Ystrad Mynach Hengoed, UK
9North Wales Organisation for Randomised Trials in Health (and Social Care), Institute of Medical & Social Care Research, Bangor University, Bangor, UK and West Wales Organisation for Rigorous Trials in Health and Social Care, Swansea University College of Medicine, Swansea, UK

*Corresponding author

Executive summary

Health Technology Assessment 2012; Vol. 16: No. 48
DOI: 10.3310/hta16480
Executive summary

Background

The growing number of people with dementia and the increasing cost of care provide a major incentive to develop and test methods of providing effective community support for a longer period of time. Most attention has been given to pharmacological interventions, but there is increasing recognition that psychosocial interventions may be equally effective and even preferable where medication has negative side effects. Reminiscence groups, run by professionals and volunteers, which use photographs, recordings and other objects to trigger personal memories, are probably the most popular therapeutic approach to working with people with dementia. Our Cochrane review prior to this trial showed that there were few studies evaluating their effectiveness and cost-effectiveness. There was, however, informal evidence that the inclusion of family carers in groups with people with dementia, notably in our pilot studies, improved relationships between people with dementia and their carers, and benefited both. A trial platform, with 57 people with dementia and their family carers participating, had enabled a treatment manual to be developed and outcome measures trialled, as well as effect sizes estimated. This had indicated significant improvements in autobiographical memory in people with dementia and depression in family carers, associated with the reminiscence intervention.

Objectives

The objectives of this trial were twofold: first, to explore the effectiveness of joint reminiscence groups for both people with dementia and their carers compared with usual care; and, secondly, to explore the cost-effectiveness of this intervention, paying particular attention to the pattern of health care, social care and voluntary sector service use and associated costs, by people with dementia and their carers.

Methods

Design

This multicentre, pragmatic randomised controlled trial had two parallel arms – an intervention group and a control group, who received care as usual. Assessments, blind to treatment allocation, were carried out at baseline, 3 months and 10 months, with the 10-month assessment being the primary end point. Randomisation was completed using a dynamic allocation method stratifying for spousal or non-spousal relationship of the dyad. Complete list randomisation for each wave of recruitment within each centre was completed. Randomisation was carried out remotely by an accredited Clinical Trials Unit when up to 24 pairs had completed baseline assessments: this was initiated by a local researcher who did not take part in follow-up assessments. The researcher arranged for those pairs (up to 12) randomised to the intervention group to attend sessions, and liaised with the group facilitator. Though participants could not be blinded to their allocated treatment, all follow-up data were gathered by blinded interviewers. In order to reduce the risk of participants occasionally and inadvertently informing researchers of the treatment they were receiving, explicit reminders were given to participants before assessment visits, and self-report measures were used wherever feasible. Assessors were also asked to record their impression of the arm to which each participant belonged, and their confidence in that prediction, so that any bias could be detected.
**Participants**

There were 488 participants (mean age 77.5 years) with mild to moderate dementia [meeting *Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition* (DSM-IV) criteria], initially living in the community, and who had a relative or other caregiver maintaining regular contact, who could act as an informant and who was willing and able to participate in the intervention. Most carers were spouses (71%). A total of 350 dyads completed the study. Where a specific subtype of dementia was recorded, in the majority of cases this was Alzheimer’s, either alone (72%) or mixed with vascular dementia (11%).

The trial took place in Bangor, Bradford, London, Manchester, Newport and Hull. Recruitment to this trial took place through mental health services for older people in each area [especially Memory Clinics, Community Mental Health Teams (CMHTs) for older people and associated professionals, including psychiatrists, occupational therapists and specialist nurses], associated day services and through relevant local voluntary sector agencies such as the Alzheimer’s Society and Age Concern. The majority of participants were recruited through NHS Memory Clinics and CMHTs for older people. Recruitment took place in 3–5 waves in each centre. Assessments were usually carried out in the participant’s home, and treatment groups held in a variety of community settings.

**Inclusion criteria**

All participants were people with dementia who:

- met the DSM-IV criteria for dementia of any type, including Alzheimer’s, vascular, Lewy body type and mixed
- were in the mild to moderate stage of dementia (Clinical Dementia Rating)
- could communicate and understand communication, shown by a score of 1 or 0 on the relevant items of the Clifton Assessment Procedures for the Elderly – Behaviour Rating Scale
- could engage in group activity
- lived in the community at the time of the baseline assessment and had a relative or other caregiver who maintained regular contact that could act as an informant and was willing and able to participate in the intervention with the person with dementia.

**Exclusion criteria**

Participants did not have any characteristics which could affect participation, for example:

- major physical illness
- sensory impairment
- disability or
- high level of agitation.

Participants entered the study only after giving signed informed consent in accordance with the provisions of the Mental Capacity Act 2005. In the event of a participant being judged to lose capacity to consent to participate during the trial, the views of a personal consultee (the carer) were sought regarding continuation. General ethical approval was obtained through the Multicentre Research Ethics Committee for Wales (ref. no. 07/MRE09/58). Participants were free to seek additional assistance and support elsewhere at any time after baseline.

**Interventions**

The intervention consisted of joint reminiscence groups held weekly for 12 consecutive weeks, followed by monthly maintenance sessions for a further 7 months. The sessions followed a treatment manual, and were led by two trained facilitators in each centre, supported by a number of volunteers. Up to 12 dyads were invited to attend each group. Each session lasted 2 hours.
Executive summary: REMCARE: reminiscence groups for people with dementia and their family caregivers

and focused on a different theme, including childhood, schooldays, working life, marriage, and holidays and journeys. Dyads were encouraged to contribute with materials brought from home. Subsequent maintenance sessions were held monthly and followed a similar pattern. Each session blended work in large and small groups, and a range of activities including art, cooking, physical re-enactment of memories, singing and oral reminiscence. The inclusion of the person with dementia is considered paramount. In the joint reminiscence groups facilitators and volunteers guided carers to allow the person with dementia to respond and to value their contribution.

Dyads in the control group received usual care which varied between and within centres.

Main outcome measures
The primary outcome measures were self-reported quality of life for the person with dementia (QoL-AD), and psychological distress for the carer [General Health Questionnaire-28 item version (GHQ-28)]. Secondary outcome measures for the person with dementia included autobiographical memory, depression, anxiety and activities of daily living. The carer reported their stress related to caregiving and their levels of anxiety and depression. Both the carer and the person with dementia rated the quality of the relationship between them. Data on service use and costs were collected for both parties. To enable exploratory cost–utility analysis, the European Quality of Life-5 Dimensions (EQ-5D) instrument was administered to both people with dementia and their family carers. Family carers were also asked to complete a proxy EQ-5D for the person with dementia.

Sample size
The trial was initially powered to detect a standardised difference of 0.38 in the QoL-AD rated by the person with dementia and 0.28 in the GHQ-28 or carer-rated QoL-AD, requiring 200 dyads in each arm to complete the 10-month assessment. This allowed for clustering effects within groups. Taking into account predicted attrition, the initial target sample size was, accordingly, 576 dyads.

During the course of the trial, this target was revised in the light of lower clustering effects and slightly better retention rates at 10 months. The revised recruitment target of 508 provided a potential sample size of 366 at 10 months' follow-up, assuming 72% retention across the 10-month period. This provided 80% power to detect a standardised difference of 0.30 in the GHQ-28 or carer-rated QoL-AD at the 5% significance level, and 80% power to detect a standardised difference of 0.31 in the patient-rated QoL-AD. The slight loss in power to detect a difference in the carer-rated measures was more than compensated for by the increased power to detect a difference on the patient-rated primary outcome measure.

Economic evaluation
From a public sector, multiagency perspective we aimed to undertake a primary cost-effectiveness analysis, using QoL-AD and the GHQ-28, separately for people with dementia and family carers in the trial. We planned to undertake exploratory secondary cost–utility analysis. A micro-costing of reminiscence groups and maintenance therapy was undertaken. Patterns of health care, social care and voluntary sector service use and associated costs by participants with dementia and their carers were evaluated, including patterns of dementia drug use and associated costs, and comparisons made between the intervention and control conditions.
Results

The final sample size of 350 dyads completing the 10-month end point assessment represents 95% of the revised target sample size. The overall attrition rate was 28% at 10 months, falling to 22% if deaths are excluded.

The intention-to-treat analysis indicated there were no differences in outcome between the intervention and control conditions on primary or secondary outcomes at the 10-month end point [self-reported QoL-AD mean difference 0.07, standard error (SE) 0.65; \( F = 0.48; p = 0.53 \)] or at the assessment carried out at 3 months. Carers of people with dementia allocated to the reminiscence intervention reported a significant increase in anxiety on a subscale of the GHQ-28 at the 10-month end point (mean difference 1.25, SE 0.5; \( F = 8.28; p = 0.04 \)). People with dementia in the intervention group made more use of local authority and NHS day care than those in the treatment as usual group. Economic analyses from a public sector, multiagency perspective indicated that joint reminiscence groups are unlikely to be cost-effective.

Compliance analyses were undertaken as specified in the analysis plan. Taking attendance at six or more of the 12 weekly sessions as an index of compliance, on the basis of clinical consensus, 70% of those allocated to the intervention received it as planned. This fell to 57% when considering those dyads who additionally attended three or more of the monthly maintenance sessions. The compliance analyses, which should be viewed as exploratory, suggested that people with dementia attending more reminiscence sessions showed improved autobiographical memory at 3 months, and an improvement in self-reported relationship quality and quality of life at 10 months. However, carers showed increased stress related to caregiving associated with more sessions attended at this point.

Conclusions

This trial does not provide support for the effectiveness or cost-effectiveness of joint reminiscence groups for people with dementia and their carers. Although there may perhaps be some beneficial effects for people with dementia who attend sessions as planned, this must be viewed in the context of raised anxiety and stress in their carers. The reasons for these discrepant outcomes need to be explored further, and may necessitate reappraisal of the movement towards joint interventions.

Implications for dementia services

The results of this trial do raise a number of issues for dementia care services. First, one-fifth of those offered the opportunity to participate in the groups declined to do so (attending only one session or none at all). Given that all these participants had agreed to enter a trial evaluating reminiscence groups, this suggests that there will be many more for whom group-based approaches of this type may not be favoured. Second, the greater use of services, such as day care, in the intervention group may signal the effects of carers meeting together and sharing experiences regarding services that might not otherwise be taken up. Third, the results of the current trial suggest that other approaches to enhancing relationships between people with dementia and their carers need to be explored, and that more work may be needed to address the anxieties and stresses that arise for carers from these relationships and the changes they observe in the person with dementia.
Recommendations for further research

1. The conventional approach, of conducting reminiscence groups with people with dementia without carers participating, was considered as a potential control comparison group in our preparatory work for this trial, but appeared at that stage to be associated with similar outcomes. Following the results of the full trial there remains uncertainty regarding the effects, on either people with dementia or their carers, of people with dementia participating in reminiscence groups with other people with dementia. Within-group and other proximal outcomes for people with dementia associated with reminiscence work would be the focus, following the lack of longer-term benefit identified in the current trial.

2. The effects of interventions that involve people with dementia and family carers together would benefit from further review. Are the negative effects on carers noted in this report a function of the specific intervention, or the joint group approach? How does this approach compare with other carer interventions? Would a mixed-methods approach provide insights as to the factors raising anxiety and stress in family carers participating in joint reminiscence groups?

Trial registration

This trial is registered as ISRCTN42430123.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Publication

How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department) Email: orders@hta.ac.uk
Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road (out-of-hours answer-phone service)
Basingstoke
Hants RG24 8QW Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header

Payment methods
Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions
NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?
Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was funded by the HTA programme as project number 06/304/229. The contractual start date was in December 2007. The draft report began editorial review in September 2011 and was accepted for publication in May 2012. The authors identified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Martin Ashton-Key, Professor Aileen Clarke, Dr Peter Davidson, Dr Tom Marshall, Professor William McGuire, Professor John Powell, Professor James Raftery, Dr Rob Riemsm, Professor Helen Snooks and Professor Ken Stein
Editorial Contact: edit@southampton.ac.uk

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
ISSN 2046-4932 (DVD)
© Queen’s Printer and Controller of HMSO 2012. This work was produced by Woods et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC. This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www.publicationethics.org/).

This journal may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA. Printed on acid-free paper in the UK by Charlesworth Press.